Drug Profile
Research programme: immunoinflammatory and neurodegenerative disorders therapeutics - Galapagos/Pharnext
Alternative Names: synergistic drug combinationsLatest Information Update: 28 Apr 2021
Price :
$50
*
At a glance
- Originator Galapagos NV; Pharnext
- Class Immunotherapies
- Mechanism of Action Immunomodulators; Inflammation mediator modulators; Neurotransmitter modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Immunological disorders; Neurodegenerative disorders
Most Recent Events
- 28 Apr 2021 No recent reports of development identified for research development in Immunological-disorders in France
- 28 Apr 2021 No recent reports of development identified for research development in Neurodegenerative-disorders in France
- 09 Sep 2019 Pharnext succeed in research and development collaboration with Galapagos